Rates and Reasons for Nonuse of Prescription Medication for Inflammatory Bowel Disease in a Referral Clinic
| Autor: | Harminder Singh, Laura E. Targownik, Eran Israeli, Sanchit Bhasin, Charles N. Bernstein |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Prescription drug Referral Disease Inflammatory bowel disease Medication Adherence Treatment Refusal 03 medical and health sciences 0302 clinical medicine Crohn Disease Internal medicine medicine Immunology and Allergy Humans Medical prescription Referral and Consultation Crohn's disease business.industry Remission Induction Gastroenterology Middle Aged medicine.disease Prognosis Ulcerative colitis 030220 oncology & carcinogenesis Physical therapy 030211 gastroenterology & hepatology Colitis Ulcerative Female business Follow-Up Studies |
| Zdroj: | Inflammatory bowel diseases. 22(4) |
| ISSN: | 1536-4844 |
| Popis: | BACKGROUND We aimed to determine the rates and reasons for nonuse of inflammatory bowel disease (IBD)-specific medication in a referral clinic. METHODS Consecutive persons with Crohn's disease (CD) (n = 423) and ulcerative colitis (UC) (n = 342) were followed in a single clinic over 2 years. At each patient visit, it was determined whether and what type of IBD-specific medications were used at that visit. If medications were not used, the reason for nonuse was recorded. Disease remission, further stratified by "clinical remission" and "deep remission" (clinical remission plus imaging evidence of remission), was considered a reason for nonuse if the attending physician believed the person was in remission and agreed for them to be off medications. RESULTS Nonuse of IBD-specific medication was seen in 121 persons with CD (29%) and 65 persons with UC (18%). In CD, increased age and disease duration were associated with nonuse; disease phenotype did not predict nonuse. In UC, disease duration was associated with nonuse but age was not. In CD, the most common reason for medication nonuse was deep remission (22.5%), followed by clinical remission (21.4%), not having seen a gastroenterologist for a lengthy period (21.4%) and nonadherence (16%). In UC, nonuse was attributed to deep remission (27.7%), followed by nonadherence (26.3%) and clinical remission (23%). CONCLUSIONS Approximately a quarter of persons with IBD attending at a tertiary care practice do not use IBD-specific medications with a higher rate in CD than UC. The decision not to use medications was deemed appropriate in approximately one-half of all nonusers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|